Abstract
Objective: Chronic rhinosinusitis (CRS) impacts an estimated 5% to 15% of people worldwide, incurring significant economic healthcare burden. There is a urgent need for the discovery of predictive biomarkers to improve treatment strategies and outcomes for CRS patients.
Study design: Cohort study of CRS patients and healthy controls using blood samples. Setting: Out-patient clinics.
Methods: Whole blood samples were collected for flow cytometric analysis. Mechanistic studies involved the transfection of human primary T cells and Jurkat cells.
Results: Our analysis began with a 63-69 year-old female patient diagnosed with refractory CRS,. Despite undergoing multiple surgeries, she continually faced sinus infections. Whole exome sequencing pinpointed a heterozygous IL-12Rb1 mutation situated in the linker region adjacent to the cytokine binding domain. When subjected to IL-12 stimulation, the patient’s CD4 T-cells exhibited diminished STAT4 phosphorylation. However, computer modeling or T-cell lines harboring the same IL-12 receptor mutation did not corroborate the hypothesis that IL-12Rb could be responsible for the reduced phosphorylation of STAT4 by IL-12 stimulation.
Upon expanding our investigation to a broader CRS patient group using the pSTAT4 assay, we discerned a subset of refractory CRS patients with abnormally low STAT4 phosphorylation.
The deficiency showed improvement both in-vitro and in-vivo after exposure to Latilactobacillus sakei (aka Lactobacillus sakei), an effect at least partially dependent on IL-12.
Conclusion: In refractory CRS patients, an identified STAT4 defect correlates with poor clinical outcomes after sinus surgery, which can be therapeutically targeted by Latilactobacillus sakei treatment. Prospective double-blind placebo-controlled trials are needed to validate our findings.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by Amerimmune. This study was supported in part by the Intramural Research Program of NIAID, NIH and internal funds to D.U. at Jackson Laboratory.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The studies involving human participants were reviewed and approved by Western Institutional Review Board (WIRB) Protocol #1285028. Written, informed consent was obtained from the individuals for the publication of any potentially identifiable images or data included in this article.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
ORCID
Michael R. Abidin M.D. 0000-0001-5679-6667
Oral Alpan M.D. 0000-0001-7467-8541
Matthew Plassmeyer PhD 0000-0001-8068-2125
Lina Kozhaya 0000-0002-1559-2278
Denise Loizou RN
Zachary Upchurch M.D 0009-0001-1357-5765
Nathan P Manes PhD 0000-0001-6701-3314
Aleksandra Nita-Lazar PhD 0000-0002-8523-605X
Mikail Dogan M.D 0000-0001-8725-9151
Derya Unutmaz, M.D. 0000-0001-8898-6633
Søren Ulrik Sønder PhD 0000-0002-4697-8421
Previous publication: This paper is uploaded to Medrxiv
Conflict of interest: The Author(s) declare(s) that there is no conflict of interest.
Contributions:
Michael R. Abidin: Design, Conduct, Analysis
Oral Alpan: Design, Conduct, Analysis
Matthew Plassmeyer: Conduct, Analysis
Lina Kozhaya: Conduct, Analysis
Denise Loizou: Conduct
Zachary Upchurch: Conduct
Nathan P Manes: Conduct, Analysis
Aleksandra Nita-Lazar: Design
Mikail Dogan: Conduct, Analysis
Derya Unutmaz: Design, Analysis
Søren Ulrik Sønder: Design, Conduct, Analysis
Funding source: This study was supported by Amerimmune. This study was supported in part by the Intramural Research Program of NIAID, NIH and internal funds to D.U. at Jackson Laboratory.
Data Availability
All data produced in the present study are available upon reasonable request to the authors